126 related articles for article (PubMed ID: 19239456)
1. p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer.
Kudahetti S; Fisher G; Ambroisine L; Foster C; Reuter V; Eastham J; Møller H; Kattan MW; Cooper CS; Scardino P; Cuzick J; Berney DM
BJU Int; 2009 Jul; 104(1):20-4. PubMed ID: 19239456
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
[TBL] [Abstract][Full Text] [Related]
3. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202.
Che M; DeSilvio M; Pollack A; Grignon DJ; Venkatesan VM; Hanks GE; Sandler HM;
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1117-23. PubMed ID: 17689883
[TBL] [Abstract][Full Text] [Related]
5. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.
Borre M; Stausbol-Gron B; Overgaard J
J Urol; 2000 Sep; 164(3 Pt 1):716-21. PubMed ID: 10953132
[TBL] [Abstract][Full Text] [Related]
6. Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments.
Kammerer-Jacquet SF; Ahmad A; Møller H; Sandu H; Scardino P; Soosay G; Beltran L; Cuzick J; Berney DM
Mod Pathol; 2019 Sep; 32(9):1303-1309. PubMed ID: 30976102
[TBL] [Abstract][Full Text] [Related]
7. Expression of p53 and bcl-2 in clinically localized prostate cancer before and after neo-adjuvant hormonal therapy.
Cesinaro AM; Migaldi M; Ferrari G; Castagnetti G; Dotti A; De Gaetani C; Ferrari P; Trentini GP
Oncol Res; 2000; 12(1):43-9. PubMed ID: 11061345
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer.
Shurbaji MS; Kalbfleisch JH; Thurmond TS
Hum Pathol; 1995 Jan; 26(1):106-9. PubMed ID: 7821906
[TBL] [Abstract][Full Text] [Related]
9. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
[TBL] [Abstract][Full Text] [Related]
10. A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease.
Severi G; FitzGerald LM; Muller DC; Pedersen J; Longano A; Southey MC; Hopper JL; English DR; Giles GG; Mills J
Cancer Med; 2014 Oct; 3(5):1266-74. PubMed ID: 24909936
[TBL] [Abstract][Full Text] [Related]
11. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study.
Berney DM; Gopalan A; Kudahetti S; Fisher G; Ambroisine L; Foster CS; Reuter V; Eastham J; Moller H; Kattan MW; Gerald W; Cooper C; Scardino P; Cuzick J
Br J Cancer; 2009 Mar; 100(6):888-93. PubMed ID: 19293807
[TBL] [Abstract][Full Text] [Related]
12. The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer.
Ritter MA; Gilchrist KW; Voytovich M; Chappell RJ; Verhoven BM
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):574-80. PubMed ID: 12062599
[TBL] [Abstract][Full Text] [Related]
13. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
[TBL] [Abstract][Full Text] [Related]
14. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.
Bauer JJ; Sesterhenn IA; Mostofi KF; McLeod DG; Srivastava S; Moul JW
Clin Cancer Res; 1995 Nov; 1(11):1295-300. PubMed ID: 9815924
[TBL] [Abstract][Full Text] [Related]
15. p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer.
Stattin P; Bergh A; Karlberg L; Nordgren H; Damber JE
Eur Urol; 1996; 30(1):65-72. PubMed ID: 8854070
[TBL] [Abstract][Full Text] [Related]
16. Molecular markers and death from prostate cancer.
Concato J; Jain D; Uchio E; Risch H; Li WW; Wells CK
Ann Intern Med; 2009 May; 150(9):595-603. PubMed ID: 19414838
[TBL] [Abstract][Full Text] [Related]
17. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
18. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy.
Rigaud J; Tiguert R; Decobert M; Hovington H; Latulippe E; Laverdiere J; Larue H; Lacombe L; Fradet Y
Prostate; 2004 Feb; 58(3):269-76. PubMed ID: 14743466
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
Vergis R; Corbishley CM; Norman AR; Bartlett J; Jhavar S; Borre M; Heeboll S; Horwich A; Huddart R; Khoo V; Eeles R; Cooper C; Sydes M; Dearnaley D; Parker C
Lancet Oncol; 2008 Apr; 9(4):342-51. PubMed ID: 18343725
[TBL] [Abstract][Full Text] [Related]
20. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
